FiercePharma

Roche aims its first Ocrevus commercials at millennials, encouraging them to take charge

Genentech has launched its first consumer campaign for multiple sclerosis drug Ocrevus, with emphasis on a particular cohort of patients: millennials. The TV ad, which features more than 10 patients, ...
WebMD

Your Guide to Ocrevus and Ocrevus Zunovo for Multiple Sclerosis (MS)

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
Seeking Alpha

Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender

It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche ...
Business Wire

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase IV CHIMES (CHaracterization of ocrelizumab In ...
Seeking Alpha

Roche's Ocrevus' 10-year data shows MS drug cuts disability progression

Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) multiple sclerosis (MS) drug Ocrevus showed that after 10 years of treatment 77% of patients with relapsing MS were free from disability progression ...
Business Wire

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...